FRCS

Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System

Retrieved on: 
목요일, 9월 8, 2022
Medical Devices, FDA, Hospitals, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Fecal incontinence, Incontinence, University of Alberta, University, INS, SNM, Department, Urinary incontinence, Health Canada, Deloitte Technology Fast 500, Quality of life, F15, Financial Times, Nasdaq, FDA, News, MRI, FRCS, U.S. FDA, Woman, SUI, Overactive bladder, Longevity, Adoption, Patient, Pharmaceutical industry, Medical device, Medical imaging, Axon reflex

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15, the companys newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15, the companys newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.
  • The Axonics F15 received regulatory approval from Health Canada following U.S. FDA approval.
  • The approval of the Axonics recharge-free system is welcome news for patients in Canada suffering from bladder and bowel dysfunction, said Gary J.
  • Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy.

Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer

Retrieved on: 
수요일, 6월 29, 2022
Bristol Myers Squibb, Patient, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hypoparathyroidism, Physiology, GLOBE, Acromegaly, FRCS, Royal College of Surgeons, Endocrinology, Food, NHS, Therapy, Clinical trial, Degenerative disease, PTH, Royal college, Twitter, University College London, Fine chemical, Pharmaceutical industry, EU

Dr. Sumeray joins Amolyt from Amryt Pharmaceuticals, where he served as chief medical officer since September 2016.

Key Points: 
  • Dr. Sumeray joins Amolyt from Amryt Pharmaceuticals, where he served as chief medical officer since September 2016.
  • We are very pleased to have Mark join our team, said Thierry Abribat, Ph.D., founder, and chief executive officer of Amolyt Pharma.
  • Prior to joining Amolyt, he spent six years as chief medical officer at Amryt Pharmaceuticals where he supervised the development, regulatory and safety departments of the company.
  • Prior to Amryt, Dr. Sumeray served as chief medical officer at Aegerion Pharmaceuticals and earlier in his career, he led the US cardiovascular and metabolic medical affairs team at Bristol-Myers Squibb.

The Radiosurgery Society's RSSearch® Patient Registry Becomes First to Incorporate GRID and LATTICE Treatment Data to Better Understand Delivery Techniques and Outcomes

Retrieved on: 
수요일, 6월 15, 2022
Doctor of Philosophy, Radiation, Science, Symposium, Publishing, RSS, FRCS, Cancer, Research, FRCR, Hospital, MD, Radiosurgery, Surgeon, Neurosurgery, Data collection, Patient, Neoplasm, Health, Principal, SAN, FLASH, Pharmaceutical industry, Medical imaging, GRID

SAN JOSE, Calif., June 15, 2022 /PRNewswire-PRWeb/ -- The Radiosurgery Society (RSS), a non-profit medical society dedicated to advancing the science and clinical practice of radiosurgery and advancing therapies, today announced that its RSSearch® Patient Registry, the longest established patient registry dedicated to SRS/SBRT managed by a professional society, now includes GRID and LATTICE treatment data. This addition marks the first patient registry to incorporate GRID and LATTICE treatment data, in an effort to better understand these delivery techniques and their associated outcomes for cancer patients.

Key Points: 
  • This addition marks the first patient registry to incorporate GRID and LATTICE treatment data, in an effort to better understand these delivery techniques and their associated outcomes for cancer patients.
  • "The RSS has been playing a vital role in advancing the science of advanced radiation techniques and the RSSearch Patient Registry has been influential in publishing real world outcomes.
  • Through the RSSearch Patient Registry, clinicians can learn from these centers' experience and better understand the risks and benefits associated with these forms of therapy.
  • The RSSearch Patient Registry is an observational, multi-platform research and data sharing registry that was established to standardize data collection from patients treated with SRS/SBRT.

Exactech Announces FDA Breakthrough Device Designation for JointMedica’s Polymotion® Hip Resurfacing System

Retrieved on: 
화요일, 5월 17, 2022
Surgery, General Health, Health, FDA, Medical Devices, Technology, Other Technology, Other Health, Physician, Program, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Surgeon, Multimedia, Patient, McMinn, Percussion section, FDA, YouTube, Instagram, Board, Metal-insulator-metal, Hospital, FRCS, LinkedIn, Twitter, Active, Diagnosis, CEO, Medical device, Pacific Ocean, MD

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Device Designation for JointMedicas Polymotion Hip Resurfacing System.

Key Points: 
  • Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Device Designation for JointMedicas Polymotion Hip Resurfacing System.
  • View the full release here: https://www.businesswire.com/news/home/20220517005313/en/
    Exactech Announces FDA Breakthrough Device Designation for JointMedicas Polymotion Hip Resurfacing System (Photo: Business Wire)
    Exactech, a minority shareholder of JointMedica Limited, is collaborating with the United Kingdom-based orthopaedic device designer and manufacturer to deliver the next generation of hip resurfacing to the global market, and holds exclusive global distribution rights to the product.
  • This designation by the FDA is a validation of our core belief at JointMedicathat our hip resurfacing device addresses an acute unmet need of relatively younger, active hip arthritis patients, said Terence Smith, Managing Director of JointMedica.
  • Through this deep collaboration Exactech and JointMedica are well positioned to bring the Polymotion Hip Resurfacing System to the global market.

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX® GPS™ Test, for the First Time in Localized Prostate Cancer Patients

Retrieved on: 
수요일, 5월 11, 2022
Electric Bond and Share Company v. Securities and Exchange Commission, Exact sciences, AUA, MCRPC, Department, Oncotype (Denmark), Exact Sciences (company), Cleveland Clinic, Physician, Patient, Guideline, Security (finance), Decision-making, American Urological Association, Neoplasm, Cancer, Diagnosis, Risk, Annual report, FRCS, MD, Multimedia, Genomic Health, Prostate cancer, Master of Science, Solution, News, Biology, GPS, Man, Medical imaging, Facebook, Urology

MADISON, Wis., May 11, 2022 /PRNewswire/ -- Exact Sciences Corp., a global leader in advanced cancer diagnostics, today announced the American Urological Association (AUA) updated their guidelines to include genomic assays, such as the Oncotype DX Genomic Prostate Score® (GPS™) test, when treating men with localized prostate cancer. The 2022 guidelines now state that clinicians may selectively use tissue-based genomic biomarkers when added risk-stratification may alter clinical decision-making. Exact Sciences will exclusively offer the at-a-glance booklets of the prostate cancer guidelines and exhibit its full portfolio of prostate cancer genomic tests at booth #647 during the AUA 2022 Annual Meeting from May 12-16 in New Orleans. This is the first in-person AUA meeting where Exact Sciences will feature its full Oncotype® portfolio of urologic genomic assays, including the Oncotype DX® GPS test for localized prostate cancer; the Oncotype MAP™ Pan-Cancer Tissue test for solid tumors, including advanced prostate cancer; and the Oncotype DX AR-V7 Nucleus Detect® test for metastatic castration-resistant prostate cancer.

Key Points: 
  • This is the first in-person AUA meeting where Exact Sciences will feature its full Oncotype portfolio of urologic genomic assays, including the Oncotype DX GPS test for localized prostate cancer; the Oncotype MAP Pan-Cancer Tissue test for solid tumors, including advanced prostate cancer; and the Oncotype DX AR-V7 Nucleus Detect test for metastatic castration-resistant prostate cancer.
  • "While every patient is unique, clinical guidelines can help physicians offer the best evidence-based care using the most current data.
  • Leading prostate cancer and pan-cancer patient advocacy groups are invited to hear the latest updates on Exact Sciences' prostate cancer genomic tests and to learn more about the company.
  • NOTE: Oncotype, Oncotype DX, Oncotype DX Genomic Prostate Score, GPS, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks of Genomic Health, Inc.

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022

Retrieved on: 
수요일, 5월 4, 2022
COVID-19, Corporate development, Florida Small Business Development Center Network, U.S. Securities and Exchange Commission, Takeda, Investment, Business, Forward-looking statement, Private Securities Litigation Reform Act, Ulcerative colitis, Senior, Time-invariant system, GLOBE, Autoimmunity, UC, Securities Exchange Act of 1934, MS, Securities Act of 1933, Safety, Research, Â, Fibrosis, Mint, Security (finance), Cubist Pharmaceuticals, FFPM, Clinical trial, Inflammatory bowel disease, FRCS, Cancer, Therapy, MD, Conditional sentence, Drug, Morphic, GI, Lists of diseases, Biology, AbbVie, Video game, Pharmaceutical industry

WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter of 2022.

Key Points: 
  • Ended first quarter 2022 with $381 million in cash and equivalents, providing runway through year-end 2024
    WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter of 2022.
  • Revenue was $2.4 million for the quarter ended March 31, 2022, compared to $3.3 million for the same quarter last year.
  • Research and development expenses were $26.5 million for the quarter ended March 31, 2022, as compared to $18.6 million for the same quarter last year.
  • General and administrative expenses were $7.6 million for the quarter ended March 31, 2022, compared to $6.0 million for the same quarter last year.

ENT and Allergy Associates Welcomes Fellowship-Trained Pediatric Otolaryngologist Alyssa Hackett, MD

Retrieved on: 
화요일, 4월 26, 2022
University, American Academy of Facial Plastic and Reconstructive Surgery, ENT, American Board of Commissioners for Foreign Missions, LLP, Northwell Health, Population, Nose, New, D.C, Sleep apnea, FACS, Montefiore Medical Center, GLOBE, Patient, Sleep, Mount Sinai Hospital, Hearing loss, Dizziness, American Board of Otolaryngology, FRCS, American Cancer Society, Human voice, Norwegian Asthma and Allergy Association, Asthma, Mount Sinai Hospital (Manhattan), Physician, Disorder, Partnership, Otorhinolaryngology, Allergy, Inner Ear, Medicine, Dentistry, MD

Tarrytown, New York, April 26, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates (ENTA), the nations preeminent otolaryngology, allergy and audiology practice, proudly announces that Dr. Alyssa Hacketta fellowship-trained pediatric otolaryngologistwill join the group as of October 1, 2022.

Key Points: 
  • Tarrytown, New York, April 26, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates (ENTA), the nations preeminent otolaryngology, allergy and audiology practice, proudly announces that Dr. Alyssa Hacketta fellowship-trained pediatric otolaryngologistwill join the group as of October 1, 2022.
  • With Dr. Hacketts arrival, ENTA will provide patients with the services of eleven pediatric fellowship-trained physicians across its substantial New York/New Jersey footprint.
  • In ENTAs Bronx office, Dr. Hackett will practice alongside fellow otolaryngologists Joseph Feghali, MD, FACS; Harrison J. Glassman, MD, FACS; Steven I. Goldstein, MD, FACS; John P. Naughton, MD; Jonathan C. Smith, MD, FACS; and Stanley Yankelowitz, MD, FRCS; as well as allergist/immunologist Dahlia Landa, MD.
  • To learn more about ENT and Allergy Associates, find the office near you or book an appointment, please visit www.entandallergy.com or call 1-855-ENTA-DOC.

Dr. M. Yaman Joins InSitu Biologics Medical Advisory Board

Retrieved on: 
금요일, 4월 22, 2022
Other Health, Research, General Health, Pharmaceutical, Oncology, Technology, Clinical Trials, Science, Biotechnology, Other Technology, Other Science, Health, Pain, Government, Cardiothoracic surgery, Mayo Clinic, Pain management, United Arab Emirates, University, Innovation, Fellowship of the Royal Colleges of Surgeons, Outline of health sciences, FACS, Leadership, Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, Sale, Infection, Royal College of Physicians and Surgeons of Canada, FRCS, Khalifa University, Company, Publication, Geography, American College, Physician, Nursing, Insitu, Royal college, Cancer, Knowledge, Pharmaceutical industry, Surgeon

InSitu Biologics is very pleased to announce the appointment of Dr. M. Yaman, FRCS, FACS, to its Medical Advisory Board.

Key Points: 
  • InSitu Biologics is very pleased to announce the appointment of Dr. M. Yaman, FRCS, FACS, to its Medical Advisory Board.
  • Dr. Yaman is the first surgeon to join InSitu Biologics Medical Advisory Board.
  • "Dr. Yaman is a well-known health care leader within the United Arab Emirates, and we are delighted that he is bringing his depth of knowledge and experience to our Medical Advisory Board, said Dr. Mark Ereth, Chief Medical Officer of InSitu Biologics.
  • Dr. Yaman is a member of the Global Advisory Council of Mayo Clinic, the Executive Advisory Council of Khalifa University, and the College Advisory Board of Abu Dhabi University College of Health Sciences.

RSNA: Artificial Intellegence Helps Radiologists Detect Bone Fractures

Retrieved on: 
화요일, 3월 29, 2022
Linda, Exercise, University, Population, FRCS, Radiation, Diagnosis, Radiological Society of North America, University of Wisconsin School of Medicine and Public Health, Society, Growth, Systematic review, Patient, Association, Judgement, OAK, Research, Nuffield Department of Population Health, CT, M.A, Meta-analysis, Intelligence, Public health, Artificial intelligence, Health, Bias, Doctor of Philosophy, RSNA, Education, AI, Rheumatology, Medical imaging, Medical device, Radiology, B.A, Fracture

OAK BROOK, Ill., March 29, 2022 /PRNewswire-PRWeb/ -- Artificial intelligence (AI) is an effective tool for fracture detection that has potential to aid clinicians in busy emergency departments, according to a study in Radiology.

Key Points: 
  • Missed or delayed diagnosis of fractures on X-ray is a common error with potentially serious implications for the patient.
  • AI may help address this problem by acting as an aid to radiologists, helping to speed and improve fracture diagnosis.
  • Of the 42 studies, 37 used X-ray to identify fractures, and five used CT.
  • It could reduce the rate of early misdiagnosis in challenging circumstances in the emergency setting, including cases where patients may sustain multiple fractures.

Acumed Launches the Ankle Syndesmosis Repair System with Acu-Sinch® Knotless™ Flexible Fixation Technology

Retrieved on: 
수요일, 3월 23, 2022
FRCS, Knotless knot, Ankle, Nail, Foot, MB, Ligamentous laxity, CEO, MD, Injury, Technology, Fluoroscopy, Surgeon, Trimalleolar fracture, MBA, Trauma, Berkshire Hathaway, Patient, Osteomed, Dentistry, Medical imaging, Acumed

HILLSBORO, Ore., March 23, 2022 /PRNewswire-PRWeb/ --Acumed is pleased to announce the launch of the Ankle Syndesmosis Repair System with Acu-Sinch Knotless technology.

Key Points: 
  • HILLSBORO, Ore., March 23, 2022 /PRNewswire-PRWeb/ --Acumed is pleased to announce the launch of the Ankle Syndesmosis Repair System with Acu-Sinch Knotless technology.
  • The system was developed by a group of surgeons focused on trauma and the needs of foot and ankle specialists.
  • "Acumed has the most complete selection of Trimalleolar fracture treatment options on the market," said Rachel Edwards, Vice President, Foot and Ankle at Acumed.
  • "Our new Ankle Syndesmosis Repair System with Acu-Sinch Knotless flexible fixation technology enhances our industry-leading portfolio, and is an example of our commitment to the specialized needs of foot and ankle surgeons worldwide."